[3,21-Dioxo-1-(trimethylazaniumyl)hexatriacontan-2-yl]oxyphosphanide

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: [3,21-Dioxo-1-(trimethylazaniumyl)hexatriacontan-2-yl]oxyphosphanide
• 英文别名: [3,21-dioxo-1-(trimethylazaniumyl)hexatriacontan-2-yl]oxyphosphanide
• 化学式: C39H78NO3P
• 分子量: 640.0
• InChiKey: KOBLANPFKUIEIN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  14.5
• 重原子数：
  44
• 可旋转键数：
  36
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.95
• 拓扑面积：
  43.4
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• Reconstructed HDL formulation
  申请人：CSL Limited

  公开号：US10603355B2

  公开（公告）日：2020-03-31

  The present invention relates to reconstituted high density lipoprotein (rHDL) formulations comprising an apolipoprotein, a lipid and a lyophilization stabilizer. Said formulations have reduced renal toxicity and good long-term stability, especially in lyophilized form.

  本发明涉及由载脂蛋白、脂质和冻干稳定剂组成的重组高密度脂蛋白（rHDL）制剂。所述制剂具有降低肾毒性和良好的长期稳定性，尤其是在冻干形式下。
• RECONSTITUTED HDL FORMULATION
  申请人：CSL Limited

  公开号：EP2916857A1

  公开（公告）日：2015-09-16
• Reconstituted HDL Formulation
  申请人：CSL Limited

  公开号：US20200397859A1

  公开（公告）日：2020-12-24

  The present invention relates to reconstituted high density lipoprotein (rHDL) formulations comprising an apolipoprotein, a lipid and a lyophilization stabilizer. Said formulations have reduced renal toxicity and good long-term stability, especially in lyophilized form.
• LIPOSOMAL ANTI-INFECTIVE FORMULATIONS TO INHIBIT NON-TUBERCULOUS MYCOBACTERIA (NTM) MICROAGGREGATE FORMATION AND ESTABLISHMENT OF NTM BIOFILM
  申请人：ARADIGM CORPORATION

  公开号：US20210007985A1

  公开（公告）日：2021-01-14

  Methods of treatment to prevent NTM microaggregate formation using formulations of liposomal ciprofloxacin. Specific liposome formulations and delivery of such for treatment of respiratory tract infections and other medical conditions, and devices and formulations used in connection with such are described.
• US9125943B2
  申请人：——

  公开号：US9125943B2

  公开（公告）日：2015-09-08